the history or family history of anaphylaxis, convulsion, epilepsy, encephalopathy and psychosis
the history of severe inoculation allergies
patients with immunodeficiency and malignant tumors during the treatment period, receiving immunosuppressive therapy (oral steroid) or HIV due to low immunity, or family members have congenital immune disease
Nonspecific immunoglobulin was injected within one month
temperature=37.1<U+2103> and infectious diseases
the history of thrombocytopenia or other thrombocytopenia with a definite diagnosis
respiratory disease, acute infection or chronic disease activity period
severe cardiovascular disease, liver and kidney disease, and complications of diabetes
infectious, suppurative and allergic dermatosis
other conditions that may affect the evaluation of the trail
any serious adverse events that have a causal relationship with the inoculation of the upper dose of the vaccine
the abnormality of 4 levels (local, systemic adverse reactions and vital signs) was judged to be related to vaccination
other new standards of exclusion criteria for first needle
other conditions that may affect the evaluation of the trail

NCT03519568_exc_T1
Observation
history
NCT03519568_exc_T2
Observation
family history
NCT03519568_exc_T3
Condition
anaphylaxis
NCT03519568_exc_T4
Condition
convulsion
NCT03519568_exc_T5
Condition
epilepsy
NCT03519568_exc_T6
Condition
encephalopathy
NCT03519568_exc_T7
Condition
psychosis
NCT03519568_exc_T8
Scope
anaphylaxis, convulsion, epilepsy, encephalopathy and psychosis
NCT03519568_exc_T9
Scope
history or family history
NCT03519568_exc_T10
Condition
inoculation allergies
NCT03519568_exc_T11
Qualifier
severe
NCT03519568_exc_T12
Observation
history
NCT03519568_exc_T13
Condition
malignant tumors
NCT03519568_exc_T14
Condition
immunodeficiency
NCT03519568_exc_T15
Temporal
during the treatment period
NCT03519568_exc_T16
Procedure
immunosuppressive therapy
NCT03519568_exc_T17
Drug
oral steroid
NCT03519568_exc_T18
Condition
HIV
NCT03519568_exc_T20
Condition
congenital immune disease
NCT03519568_exc_T21
Scope
immunodeficiency and malignant tumors
NCT03519568_exc_T19
Observation
family members
NCT03519568_exc_T22
Drug
Nonspecific immunoglobulin
NCT03519568_exc_T23
Temporal
within one month
NCT03519568_exc_T24
Measurement
temperature
NCT03519568_exc_T25
Value
=37.1<U+2103>
NCT03519568_exc_T26
Condition
infectious diseases
NCT03519568_exc_T27
Condition
thrombocytopenia
NCT03519568_exc_T28
Observation
history
NCT03519568_exc_T29
Qualifier
other
NCT03519568_exc_T30
Condition
thrombocytopenia
NCT03519568_exc_T31
Condition
respiratory disease
NCT03519568_exc_T32
Condition
acute infection
NCT03519568_exc_T33
Condition
chronic disease activity period
NCT03519568_exc_T34
Qualifier
severe
NCT03519568_exc_T35
Condition
cardiovascular disease
NCT03519568_exc_T36
Condition
kidney disease
NCT03519568_exc_T37
Condition
nd ki , and c
NCT03519568_exc_T38
Condition
complications
NCT03519568_exc_T39
Condition
diabetes
NCT03519568_exc_T40
Condition
us, suppur is
other c
NCT03519568_exc_T41
Condition
ive and all is
other c
NCT03519568_exc_T42
Condition
allergic dermatosis
NCT03519568_exc_T44
Qualifier
serious
NCT03519568_exc_T45
Condition
adverse events
NCT03519568_exc_T46
Procedure
inoculation of the upper dose of the vaccine